ES2145997T3 - Composiciones de aminoacidos y uso de las mismas en la nutricion clinica. - Google Patents

Composiciones de aminoacidos y uso de las mismas en la nutricion clinica.

Info

Publication number
ES2145997T3
ES2145997T3 ES96904849T ES96904849T ES2145997T3 ES 2145997 T3 ES2145997 T3 ES 2145997T3 ES 96904849 T ES96904849 T ES 96904849T ES 96904849 T ES96904849 T ES 96904849T ES 2145997 T3 ES2145997 T3 ES 2145997T3
Authority
ES
Spain
Prior art keywords
tnf
amino acid
levels
same
acid compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96904849T
Other languages
English (en)
Inventor
Heinz Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis Nutrition AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08392694 external-priority patent/US5656608B1/en
Priority claimed from GBGB9512100.0A external-priority patent/GB9512100D0/en
Application filed by Novartis Nutrition AG filed Critical Novartis Nutrition AG
Application granted granted Critical
Publication of ES2145997T3 publication Critical patent/ES2145997T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION CONTEMPLA EL USO DE AL MENOS UN AMINOACIDO SELECCIONADO DEL GRUPO GLICINA, ALANINA Y SERINA, O LAS SALES FISIOLOGICAMENTE ACEPTABLES DE LOS MISMOS EN LA PREPARACION DE UN MEDICAMENTO O FORMULACION NUTRICIONAL PARA LA DISMINUCION DE LOS NIVELES DE FACTOR DE NECROSIS TUMORAL (TNF) EN PACIENTES EN LOS QUE DICHOS NIVELES SOBREPASAN LOS MEDIADOS POR LA HOMEOSTASIS FISIOLOGICA Y LA INFLAMACION LOCAL. TAL DISMINUCION DE LOS NIVELES DE TNF PUEDE LOGRARSE POR INHIBICION O DISMINUCION DE: (I) LA PRODUCCION DE FACTOR DE NECROSIS TUMORAL (TNF) POR LAS CELULAS DEL TIPO MACROFAGO; (II) LA LIBERACION DE TNF POR LAS CELULAS DE TIPO MACROFAGO; Y/O (III) LA UNION DE TNF POR RECEPTORES DE TNF.
ES96904849T 1995-02-23 1996-02-22 Composiciones de aminoacidos y uso de las mismas en la nutricion clinica. Expired - Lifetime ES2145997T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08392694 US5656608B1 (en) 1995-02-23 1995-02-23 Amino acid compositions and methods of treatment using same
GBGB9512100.0A GB9512100D0 (en) 1995-06-14 1995-06-14 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
ES2145997T3 true ES2145997T3 (es) 2000-07-16

Family

ID=26307213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96904849T Expired - Lifetime ES2145997T3 (es) 1995-02-23 1996-02-22 Composiciones de aminoacidos y uso de las mismas en la nutricion clinica.

Country Status (18)

Country Link
EP (1) EP0810829B1 (es)
JP (1) JPH11501301A (es)
KR (1) KR19980702436A (es)
CN (1) CN1175887A (es)
AT (1) ATE191615T1 (es)
AU (1) AU710527B2 (es)
BR (1) BR9607336A (es)
CA (1) CA2210499A1 (es)
CZ (1) CZ266797A3 (es)
DE (1) DE69607750T2 (es)
DK (1) DK0810829T3 (es)
ES (1) ES2145997T3 (es)
FI (1) FI972744A (es)
HU (1) HUP9800049A3 (es)
NO (1) NO973884L (es)
PL (1) PL182205B1 (es)
PT (1) PT810829E (es)
WO (1) WO1996025861A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US6096785A (en) * 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
JP2000515874A (ja) * 1996-07-30 2000-11-28 ノバルテイス・ニユートリシヨン・アクチエンゲゼルシヤフト アミノ酸組成物、ならびに腫瘍の成長および転移の処置におけるその使用
GB9701674D0 (en) * 1997-01-28 1997-03-19 Novartis Nutrition Ag Use of organic compounds
EP0882451B1 (en) * 1997-06-05 2004-05-12 Novartis Nutrition AG Glycine for prevention or treatment of transplant rejection
US6310097B1 (en) * 1997-07-28 2001-10-30 Riken Protecting and survival promoting agent for central nervous cell
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
DE10257360A1 (de) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastro-intestinal verabreichbare Formulierung und deren Verwendung
EP1665940A4 (en) 2003-09-02 2011-01-19 Bbk Bio Corp DIETETIC FOODSTUFF
EP1591118A1 (en) 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
KR100555904B1 (ko) * 2004-05-19 2006-03-03 주식회사 오스코텍 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물
EP2032170B1 (en) * 2006-06-14 2012-11-28 N.V. Nutricia Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
JP5979816B2 (ja) 2008-01-04 2016-08-31 ネステク ソシエテ アノニム 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
NZ615091A (en) * 2009-06-08 2015-03-27 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
KR101213825B1 (ko) * 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
KR101758424B1 (ko) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
JP6378307B2 (ja) 2013-03-11 2018-08-22 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 肺機能を改善するためならびに放射線誘発肺合併症の予防および／または処置のための物質および方法
BR112017010832A2 (pt) 2014-11-24 2017-12-26 Entrinsic Health Solutions Llc composições de aminoácido para o tratamento de sintomas de doença
EP3355878A1 (en) 2015-10-02 2018-08-08 N.V. Nutricia Glycine for use in tolerance induction in allergic patients
FR3041882B1 (fr) * 2015-10-06 2019-04-12 Universite D'angers Preparation pharmaceutique pour le traitement preventif de lesions d'ischenie reperfusion
MX2019003821A (es) 2016-10-04 2019-12-18 Univ Florida Composiciones de aminoacidos y usos de las mismas.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591893B1 (fr) * 1985-12-19 1988-11-10 Centre Nat Rech Scient Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
ATE174794T1 (de) * 1991-09-27 1999-01-15 Univ Texas Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease

Also Published As

Publication number Publication date
JPH11501301A (ja) 1999-02-02
DK0810829T3 (da) 2000-08-28
HUP9800049A2 (hu) 1998-05-28
DE69607750T2 (de) 2000-08-31
FI972744A0 (fi) 1997-06-25
EP0810829A1 (en) 1997-12-10
MX9706140A (es) 1997-11-29
PL182205B1 (pl) 2001-11-30
HUP9800049A3 (en) 1999-01-28
NO973884L (no) 1997-10-17
AU710527B2 (en) 1999-09-23
PL321238A1 (en) 1997-11-24
ATE191615T1 (de) 2000-04-15
CA2210499A1 (en) 1996-08-29
NO973884D0 (no) 1997-08-22
DE69607750D1 (de) 2000-05-18
WO1996025861A1 (en) 1996-08-29
KR19980702436A (ko) 1998-07-15
FI972744A (fi) 1997-08-22
AU4879596A (en) 1996-09-11
EP0810829B1 (en) 2000-04-12
CN1175887A (zh) 1998-03-11
PT810829E (pt) 2000-08-31
BR9607336A (pt) 1997-11-25
CZ266797A3 (cs) 1998-03-18

Similar Documents

Publication Publication Date Title
ES2145997T3 (es) Composiciones de aminoacidos y uso de las mismas en la nutricion clinica.
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
BRPI0514411A (pt) formulação, e, método de produzir uma formulação
CO4890856A1 (es) CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
CY1116233T1 (el) Δισφωσφονικα οξεα για τη θεραπευτικη αγωγη και προληψη της οστεοπορωσης
BR9916367A (pt) Novos compostos de bifenila e de análogos debifenila como antagonistas da integrina
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
AR024516A1 (es) Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
AR030305A1 (es) Composicion que comprende sales de acido o-acetilsalicilico con aminoacidos basicos, un procedimiento para su preparacion, uso de dicha composicion para la manufactura de un medicamento
HUP0400988A2 (hu) Kombinált NEP/MP-gátló aktivitással rendelkező vegyületek felhasználása gyógyszerek előállítására
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
CY1107349T1 (el) Αλφα-κετογλουταρικα ενεργα συστατικα και σκευασματα που τα περιεχουν
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
TR200103151T2 (tr) Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
UY26911A1 (es) Ácidos amino (oxo) acéticos inhibidores de la proteina tirosina fosfatasa
DE60036199D1 (de) Proteaseresistente flint-analoge
AR046454A1 (es) Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
AR030923A1 (es) Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia
ATE312810T1 (de) Feste zusammensetzungen für orale verabreichung die nicht-hygroskopische salze von l-karnitin und alkanoyl-l-karnitin mit taurinchlorid enthalten
ES2167889T3 (es) Composiciones solidas adecuadas para administracion oral que comprenden tartrato de l-carnitina colina o tartrato de alcanoil-l-carnitina colina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 810829

Country of ref document: ES